Company profile for Atea Pharmaceuticals

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Atea is a clinical stage biopharmaceutical company discovering and developing best-in-class therapies to address the unmet medical needs of patients with life-threatening viral diseases. Our medicinal chemistry and virology expertise, bolstered by our collective experience in drug development, enables us to pioneer new advancements in antiviral science. Leveraging the power of our medicinal chemistry expertise and purine nucle...
Atea is a clinical stage biopharmaceutical company discovering and developing best-in-class therapies to address the unmet medical needs of patients with life-threatening viral diseases. Our medicinal chemistry and virology expertise, bolstered by our collective experience in drug development, enables us to pioneer new advancements in antiviral science. Leveraging the power of our medicinal chemistry expertise and purine nucleotide prodrug platform, we’re able to discover, optimize, and rapidly advance novel drug candidates for viral targets such as SARS-CoV-2.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
125 Summer Street Boston, MA 02110
Telephone
Telephone
(857) 284-8891
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/19/3190788/0/en/Atea-Pharmaceuticals-to-Present-at-the-8th-Annual-Evercore-Healthcare-Conference.html

GLOBENEWSWIRE
19 Nov 2025

https://www.globenewswire.com/news-release/2025/11/12/3186782/0/en/Atea-Pharmaceuticals-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-Update.html

GLOBENEWSWIRE
12 Nov 2025

https://www.globenewswire.com/news-release/2025/11/07/3183594/0/en/Atea-Pharmaceuticals-Presents-New-Data-Supporting-the-Fixed-Dose-Combination-of-Bemnifosbuvir-and-Ruzasvir-as-a-Potential-Best-in-Class-Regimen-for-Treatment-of-Hepatitis-C-Virus-I.html

GLOBENEWSWIRE
07 Nov 2025

https://www.globenewswire.com/news-release/2025/11/05/3181255/0/en/Atea-Pharmaceuticals-to-Host-Third-Quarter-2025-Financial-Results-and-Business-Update-Conference-Call-on-November-12-2025.html

GLOBENEWSWIRE
05 Nov 2025

https://www.globenewswire.com/news-release/2025/10/22/3170954/0/en/Atea-Pharmaceuticals-to-Host-Virtual-HCV-KOL-Panel-Event-on-November-13-2025.html

GLOBENEWSWIRE
22 Oct 2025

https://www.globenewswire.com/news-release/2025/10/07/3162443/0/en/Atea-Pharmaceuticals-to-Present-New-Data-Supporting-Combination-of-Bemnifosbuvir-and-Ruzasvir-as-Potential-Best-in-Class-Regimen-for-Treatment-of-Hepatitis-C-Virus-Infection-at-The.html

GLOBENEWSWIRE
07 Oct 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty